drugset / Trial / NCT01329900

Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas

NCT01329900

Phase 2 Completed 50 enrolled M.D. Anderson Cancer Center Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if it is possible to collect stem cells after ofatumumab and chemotherapy treatment. This study will also evaluate side-effects, number of stem cells collected, and the number of procedures that are needed to collect enough stem cells.

Timeline

Start
2011-08-22
Primary completion
2019-07-21
Completion
2019-07-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Ofatumumab Monoclonal antibody 2000 mg Intravenous
Background 2-MERCAPTOETHANESULFONIC ACID Small molecule 2.66 g Intravenous
Background Etoposide Small molecule 150 mg/m2 Intravenous
Background G-CSF Unknown 6 ug/kg Subcutaneous
Background Ifosfamide Small molecule 3.33 g Intravenous

Indications